Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Substantial advances in mechanical and adjunctive pharmacological therapies have reduced the consequences of ischemic heart disease. Despite these advances, cardiovascular disease and its major contributor coronary artery disease continue to accrue substantial morbidity and mortality. Metabolic therapies (ranging from insulin to fatty acid oxidation inhibitors and late sodium channel current inhibitors) represent a novel and immediately clinical relevant class of therapies that can contribute to improving patient outcomes. In the current article, I will discuss the basic biology of cardiac metabolism and the clinical efficacy of agents, some of which have direct clinical applicability. As well as outlining the considerations that may culminate in the effective deployment of these agents in the care of patients, I also consider the likely future directions for metabolic therapy in cardiovascular disease.

Type

Journal article

Journal

Heart and Metabolism

Publication Date

01/12/2011

Pages

9 - 13